LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Apogee Therapeutics Announces Positive Interim Phase 1 Results From APG990 Healthy Volunteer Trial 3/3/2025 6:45:32 AM
  • Apogee Therapeutics Doses First Participants Dosed In Phase 1 Clinical Trial Of APG333 12/10/2024 7:12:18 AM
  • Wedbush Is Cutting Apogee Therapeutics, Inc. (APGE) FY25 Estimate To -3.93 From -3.90 12/2/2024 4:45:00 PM
  • Wedbush Is Cutting Apogee Therapeutics, Inc. (APGE) Q4 25 Estimate To -0.97 From -0.94 12/2/2024 4:44:48 PM
  • Wedbush Is Lowering Apogee Therapeutics, Inc. (APGE) Q3 25 Estimate To -0.97 From -0.95 12/2/2024 4:44:38 PM
  • Wedbush Reiterates Apogee Therapeutics, Inc. (APGE) At Outperform With $90 Up From $87 Price Target 12/2/2024 4:44:15 PM
  • Apogee Therapeutics Highlights Progress Of Novel Biologic Programs For I&I Diseases At 2024 Inaugural R&D Day 12/2/2024 6:09:02 AM
  • Wedbush Is Cutting Apogee Therapeutics, Inc. (APGE) FY25 Estimate To -3.90 From -3.04 11/12/2024 11:19:02 PM
  • Wedbush Is Cutting Apogee Therapeutics, Inc. (APGE) FY24 Estimate To -3.10 From -2.67 11/12/2024 11:18:50 PM
  • Wedbush Is Lowering Apogee Therapeutics, Inc. (APGE) Q4 24 Estimate To -0.97 From -0.72 11/12/2024 11:18:39 PM
  • Wedbush Reiterates Apogee Therapeutics, Inc. (APGE) At Outperform With $87 Price Target 11/12/2024 11:18:18 PM
  • Wedbush Reiterates Apogee Therapeutics, Inc. (APGE) At Outperform With $87 Price Target 10/25/2024 7:04:43 PM
  • Wedbush Reiterates Apogee Therapeutics, Inc. (APGE) At Outperform With $87 Price Target 10/24/2024 5:37:50 PM
  • Apogee Therapeutics Appoints Jeff Hartness As Chief Commercial Officer 9/9/2024 7:09:06 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap